Interestingly, in the two tumors showing variation in GNA11 mutation, the areas with strong pERK1/2 immunostaining showed no detectable GNA11 mutation, while the tumor areas with no pERK1/2 immunostaining showed heterozygous GNA11 mutation, Figure 2A. This evidence concerns the gene GNA11 and neoplasm.